Previous studies are consistent with the prognostic value of serum leptin for overall survival rates in patients with gastric adenocarcinoma, hepatocellular carcinoma and colorectal adenocarcinoma (22–24). This evidence concerns the gene LEP and hepatocellular carcinoma.